John will lead the company as CEO to explore the potential of a novel therapeutic for treatment of acute heart attacks into clinical development This novel protein technology has been shown in preclinical studies to protect heart cells and minimize the consequences of a heart attack Heart disease continues to be the number one cause…

Agreement grants Freeline rights to develop and commercialise AAV gene therapies using cardiac protein genes identified by Forcefield London UK, 4 April 2023 Forcefield Therapeutics (“Forcefield”) Ltd, a pioneer of best-in-class therapeutics to protect heart function by arresting the loss of cardiomyocytes following myocardial infarction, and Freeline Therapeutics have entered into an exclusive patent and…

Preclinical data outlining the mechanisms of three proteins shown to restore heart function following acute myocardial infarction (heart attack) presented at AHA Proteins were identified by FunSel technology and developed by Forcefield. London UK, 7 November 2022 Forcefield Therapeutics (“Forcefield”) Ltd, a pioneer of best-in-class therapeutics to protect heart function by arresting the loss of…

Publication in Science Translational Medicine describes three proteins which have been shown to preserve heart function following acute myocardial infarction (heart attack) via a unique combination of cardioprotective mechanisms in preclinical proof-of-concept studies Research was advanced by Forcefield Therapeutics at King’s College London and supported by the British Heart Foundation. Read Article London UK, 31…

For this article in the Daily Telegraph, Hannah Boland spoke with scientific founder Prof. Mauro Giacca, and CEO Richard Francis about Forcefield’s research into identifying proteins which have the potential to arrest the death of critical cells after a heart attack and minimize the risk of heart failure. Read Article About Forcefield Therapeutics Ltd. Forcefield…

Paul Schloesser from Endpoints News wrote on Forcefield Therapeutics’ launch following a $6.9m investment in the company from UK life science investor Syncona Limited. Paul spoke to Richard Francis, CEO, and Dan Gliddon, SVP Early Development, about the science behind Forcefield and how Forcefield is looking at building drugs that can reduce the number of…

Andrew McConaghie from Scrip spoke to Prof. Mauro Giacca, scientific founder of Forcefield and Richard Francis, CEO,on the company’s novel platform for discovering protective tissue factors and turning them into therapies, with heart failure as its first target as well as our goal of developing a protein-based therapy for acute myocardial infarction (MI) to preserve…

Nuala Moran at BioWorld spoke to Prof. Mauro Giacca, scientific founder of Forcefield, Richard Francis, CEO, and Chris Hollowood, Chief Investment Officer of Syncona, on Forcefield’s launch, it’s backing from Syncona and how Forcefield aims to protect heart function following myocardial infarction, helping sustain cardiac function and preventing clinical changes in the heart outline our…

On Forcefield Therapeutics’ unveiling in the UK, Jonathan Smith for Labiotech wrote on the company’s mission to develop the first drugs to safeguard heart muscle from damage during heart attacks. Read Article About Forcefield Therapeutics Ltd. Forcefield Therapeutics Ltd (Forcefield Tx) is a pioneer of best-in-class therapeutics to retain heart function via protection of cardiomyocytes.…

New biotechnology company launched to develop pioneering, best-in-class therapeutics to protect heart function following acute myocardial infarction (AMI). London UK, 25 April 2022 Forcefield Therapeutics (“Forcefield”) Ltd, a pioneer of best-in-class therapeutics to protect heart function by arresting the loss of cardiomyocytes following myocardial infarction, officially launches today following a £5.5 million commitment from Syncona…